#1 Clinical Trials Search in Europe

Irinotecan Hydrochloride

Irinotecan Hydrochloride, a chemotherapy drug, is being extensively studied in clinical trials for its potential in treating various types of cancer. These trials aim to evaluate its efficacy, safety, and optimal dosing when used alone or in combination with other drugs. The research spans across different cancer types, including solid tumors, brain metastases, and gastrointestinal cancers, offering hope for patients with hard-to-treat or advanced stage cancers.

Table of Contents

What is Irinotecan Hydrochloride?

Irinotecan Hydrochloride, also known by brand names such as Camptosar, Campto, or CPT-11, is a chemotherapy drug used to treat various types of cancer[1]. It belongs to a class of medications called topoisomerase I inhibitors, which work by interfering with the DNA replication of cancer cells, ultimately stopping their growth and division[2].

What Conditions Does Irinotecan Treat?

Irinotecan is primarily used to treat several types of cancer, including:

  • Metastatic Colorectal Cancer: This is cancer that has spread from the colon or rectum to other parts of the body[1][3].
  • Advanced Solid Tumors: These are cancers that form solid masses in various parts of the body[2].
  • Brain and Central Nervous System Tumors: Specifically, it has been studied in the treatment of glioblastoma multiforme, an aggressive type of brain cancer[4].
  • Non-Small Cell Lung Cancer: This is a type of lung cancer that accounts for most lung cancer cases[5].

How is Irinotecan Administered?

Irinotecan is typically administered intravenously (through a vein) in a hospital or clinic setting. The dosage and frequency can vary depending on the specific condition being treated and the patient’s individual factors. Some common administration schedules include:

  • 180 mg/m² given every 2 weeks[1]
  • 350 or 700 mg/m² given every 3 weeks[4]
  • 125 mg/m² given on days 1, 8, 15, and 22 of a 6-week cycle[5]

The duration of each infusion is typically around 90 minutes[1]. Your healthcare provider will determine the most appropriate dosage and schedule for your specific situation.

Irinotecan in Combination Therapies

Irinotecan is often used in combination with other cancer treatments to enhance its effectiveness. Some common combination therapies include:

  • Irinotecan with Cetuximab: This combination is used in treating metastatic colorectal cancer, especially in patients who have previously responded to cetuximab-containing therapy[3].
  • Irinotecan with Thalidomide: This combination has been studied for treating glioblastoma multiforme after radiation therapy[4].
  • FOLFOXIRI plus Bevacizumab: This regimen combines irinotecan with oxaliplatin, 5-fluorouracil, leucovorin, and bevacizumab for treating metastatic colorectal cancer[6].
  • Irinotecan with Temozolomide: This combination has been studied for treating recurrent glioblastoma[7].

Potential Side Effects

Like all chemotherapy drugs, irinotecan can cause side effects. Some potential side effects include:

  • Neutropenia: A decrease in white blood cells, which can increase the risk of infections[1].
  • Diarrhea: This can be severe and may require treatment[1].
  • Nausea and vomiting[1].
  • Fatigue
  • Hair loss
  • Anemia: A decrease in red blood cells, which can cause fatigue.

Your healthcare team will monitor you closely for these side effects and can provide treatments to help manage them.

Ongoing Research and Clinical Trials

Researchers continue to study irinotecan to find new ways to use it effectively and to improve patient outcomes. Some areas of ongoing research include:

  • Using irinotecan in combination with newer targeted therapies[1].
  • Studying the effectiveness of irinotecan in treating specific genetic subtypes of cancer[5].
  • Investigating the use of irinotecan in perioperative treatment (treatment given before and after surgery) for colorectal cancer liver metastases[8].
  • Exploring different dosing schedules to improve efficacy and reduce side effects[7].

If you’re interested in participating in a clinical trial involving irinotecan, talk to your oncologist about potential opportunities.

Aspect Details
Drug Name Irinotecan Hydrochloride
Drug Class Topoisomerase I inhibitor
Administration Intravenous (IV)
Cancer Types Studied Solid tumors, brain metastases, esophageal, stomach, breast, biliary tract
Combination Therapies Erlotinib hydrochloride, trifluridine/tipiracil
Key Objectives Efficacy, safety, optimal dosing, pharmacokinetics
Common Side Effects Diarrhea, nausea, vomiting, fatigue, decreased blood cell counts
Outcome Measures Progression-free survival, overall survival, tumor response rates

FAQ

  • What is Irinotecan Hydrochloride? Irinotecan Hydrochloride is a chemotherapy drug that works by stopping the growth of cancer cells. It belongs to a class of drugs called topoisomerase I inhibitors, which interfere with the DNA replication of cancer cells.
  • What types of cancer are being studied with Irinotecan Hydrochloride? Clinical trials are exploring the use of Irinotecan Hydrochloride in various cancers, including solid tumors, brain metastases, esophageal and stomach cancer, breast cancer, and biliary tract cancer.
  • How is Irinotecan Hydrochloride administered? Irinotecan Hydrochloride is typically administered intravenously (through a vein) over a period of 60-90 minutes. The frequency and duration of treatment can vary depending on the specific trial and cancer type being studied.
  • What are some common side effects of Irinotecan Hydrochloride? Common side effects may include diarrhea, nausea, vomiting, fatigue, and decreased blood cell counts. However, the severity and frequency of side effects can vary among patients and are closely monitored during clinical trials.
  • Are there any combination therapies being studied with Irinotecan Hydrochloride? Yes, several trials are investigating Irinotecan Hydrochloride in combination with other drugs. For example, it's being studied with erlotinib hydrochloride for solid tumors and with trifluridine/tipiracil for biliary tract cancers.

Ongoing Clinical Trials on Irinotecan Hydrochloride

  • A study of irinotecan, fluorouracil, calcium folinate, zimberelimab, and domvanalimab for patients with metastatic gastro-enteropancreatic neuroendocrine carcinoma.

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effects of Different Dosing Schedules of Irinotecan Hydrochloride, Calcium Folinate, and Fluorouracil in Patients with Metastatic Colorectal Cancer

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Hungary

  • Study on the Safety and Effectiveness of mFOLFIRINOX with or without BNT321 for Patients with Resected Pancreatic Cancer

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Denmark France Germany Spain

  • Study on the Effectiveness of Floxuridine and Drug Combination for Patients with Unresectable Colorectal Liver Metastases

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study of RMC-6236 compared to standard therapy in previously treated metastatic pancreatic ductal adenocarcinoma

    Not recruiting

    1 1 1 1
    Investigated drugs:
    France Germany Italy Spain

  • Study on the Safety and Effectiveness of Mitazalimab with Chemotherapy for Patients with Metastatic Pancreatic Cancer

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium France Spain

  • Study on the Safety and Effectiveness of ABTL0812 with Drug Combination for Patients with Metastatic Pancreatic Cancer

    Not recruiting

    1 1
    Investigated drugs:
    France Spain

  • Study on Short-Course Radiotherapy and Chemotherapy with Fluorouracil, Irinotecan, and Oxaliplatin for Patients with Locally Advanced Rectal Cancer

    Not recruiting

    1 1 1
    Investigated drugs:
    Italy

  • Study of SCO-101 with FOLFIRI for Patients with Metastatic Colorectal Cancer Resistant to FOLFIRI

    Not recruiting

    1 1 1
    Investigated drugs:
    Spain

  • Study of Abemaciclib, Irinotecan, and Temozolomide for Patients with Relapsed or Refractory Ewing’s Sarcoma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

Glossary

  • Topoisomerase I inhibitor: A class of drugs that interfere with the DNA replication of cancer cells by inhibiting an enzyme called topoisomerase I, which is essential for cell division.
  • Intravenous (IV): A method of administering medication directly into a vein using a needle or tube.
  • Solid tumor: An abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign or malignant.
  • Metastases: The spread of cancer cells from the primary site (where it started) to other parts of the body.
  • Biliary tract cancer: A type of cancer that occurs in the bile ducts, which carry digestive fluid bile from the liver to the small intestine.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall survival (OS): The length of time from either the date of diagnosis or the start of treatment for a disease that patients are still alive.
  • Dose-limiting toxicity: Side effects of a drug that are severe enough to prevent an increase in dose or level of treatment.
  • Maximum tolerated dose (MTD): The highest dose of a drug or treatment that does not cause unacceptable side effects.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.

References

  1. https://clinicaltrials.gov/study/NCT01925274
  2. https://clinicaltrials.gov/study/NCT00002902
  3. https://clinicaltrials.gov/study/NCT02296203
  4. https://clinicaltrials.gov/study/NCT00039468
  5. https://clinicaltrials.gov/study/NCT01654081
  6. https://clinicaltrials.gov/study/NCT01163396
  7. https://clinicaltrials.gov/study/NCT01308632
  8. https://clinicaltrials.gov/study/NCT02086656